TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis.
作者： Qiang Tong , Dong-Bao Zhao , Punam Bajracharya , Xia Xu , Rui-Na Kong
DOI: 10.2217/PGS.12.133
关键词:
摘要: Aim: To evaluate whether polymorphisms at -857, -1031, -308 and -238 positions of the TNF-α gene influence response to TNF-α-blocker therapy in Chinese Han patients with ankylosing spondylitis. Patients & methods: A total 106 spondylitis were recruited genotyped for polymorphisms. In total, 32 received infliximab 74 a recombinant human receptor II–IgG Fc fusion protein (rhTNFR–Fc). At end 12 weeks, assessed using Assessment SpondyloArthritis International Society (ASAS) 20, 40, 50 70 criteria. Results: Polymorphisms did not affect therapeutic response. The -857 C/C genotype (p = 0.0021) responded better therapy. -1031 T/T 0.0004) showed outcome. Conclusion: patients, are unable predict response; however, T/T...
futuremedicine.com 
sci-hub.se 参考文章(43)
Yun-feng Pan, Feng Huang, Liang-jing Lü, Zun-ming Yang, Dong-hai Wu, Jian-lin Huang, Shun-le Chen, Shi Chen, Li Ma, Jie Zhang, Zhan-guo Li, [A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis]. Chinese Journal of Internal Medicine. ,vol. 49, pp. 741- ,(2010)
Zheng Zhao, Feng Huang, Ya-mei Zhang, Yi Zheng, Jie Zhang, Hua-xiang Wu, Jian-hua Xu, Zhi-wei Chen, Xing-fu Li, [A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis]. Chinese Journal of Internal Medicine. ,vol. 50, pp. 1043- ,(2011)
P. V. Voulgari, I. Georgiou, A. Chatzikyriakidou, A. A. Drosos, The role of tumor necrosis factor (TNF)-α and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis Clinical and Experimental Rheumatology. ,vol. 27, pp. 645- 648 ,(2009)
D D O'Rielly, N M Roslin, J Beyene, A Pope, P Rahman, TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics Journal. ,vol. 9, pp. 161- 167 ,(2009) , 10.1038/TPJ.2009.7
Sjef Van Der Linden, Hans A. Valkenburg, Arnold Cats, Evaluation of Diagnostic Criteria for Ankylosing Spondylitis Arthritis & Rheumatism. ,vol. 27, pp. 361- 368 ,(1984) , 10.1002/ART.1780270401
Yiannis Vasilopoulos, Marilena Manolika, Efterpi Zafiriou, Theologia Sarafidou, Vasilis Bagiatis, Sabine Krüger-Krasagaki, Androniki Tosca, Aikaterini Patsatsi, Dimitris Sotiriadis, Zissis Mamuris, Angeliki Roussaki-Schulze, Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population Molecular Diagnosis & Therapy. ,vol. 16, pp. 29- 34 ,(2012) , 10.1007/BF03256427
Bing Li, Pei Wang, Hui Li, The association between TNF-α promoter polymorphisms and ankylosing spondylitis: a meta-analysis Clinical Rheumatology. ,vol. 29, pp. 983- 990 ,(2010) , 10.1007/S10067-010-1499-Y
Gilberto Vargas-Alarcón, Julio Casasola-Vargas, José Manuel Rodríguez-Pérez, Gabriela Huerta-Sil, Nonanzit Pérez-Hernández, John Londoño, Cesar Pacheco-Tena, Mario H. Cardiel, Julio Granados, Rubén Burgos-Vargas, Tumor Necrosis Factor-α Promoter Polymorphisms in Mexican Patients With Spondyloarthritis Human Immunology. ,vol. 67, pp. 826- 832 ,(2006) , 10.1016/J.HUMIMM.2006.07.009
M.-Y. Shiau, M.-K. Lo, C.-P. Chang, T.-P. Yang, K.-T. Ho, Y.-H. Chang, Association of tumour necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan Annals of the Rheumatic Diseases. ,vol. 66, pp. 562- 563 ,(2006) , 10.1136/ARD.2006.065888
Wouter M. Kooloos, Judith A.M. Wessels, Tahar van der Straaten, Tom W.J. Huizinga, Henk-Jan Guchelaar, Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. Drug Discovery Today. ,vol. 14, pp. 837- 844 ,(2009) , 10.1016/J.DRUDIS.2009.05.017